Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

121.38 -0.48 (-0.39%)

Streaming Delayed Price Updated: 12:09 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

August 01, 2024

Via Benzinga

Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗

August 01, 2024

Via Benzinga

Merck Analysts Slash Their Forecasts After Q2 Results ↗

July 31, 2024

Via Benzinga

Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry ↗

July 31, 2024

Via Benzinga

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗

July 31, 2024

Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.

Via InvestorPlace

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? ↗

July 31, 2024

Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.

Via The Motley Fool

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

Merck & Co's Options: A Look at What the Big Money is Thinking ↗

July 26, 2024

Via Benzinga

Smart Money Is Betting Big In MRK Options ↗

July 25, 2024

Via Benzinga

Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone ↗

July 31, 2024

Market sentiment declines as Fear & Greed index moves to 'Fear' zone. Dow Jones gains ahead of major earnings and Fed policy decision.

Via Benzinga

Topics Economy Stocks

Merck (MRK) Q2 2024 Earnings Call Transcript ↗

July 30, 2024

MRK earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗

July 30, 2024

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2024

Via Benzinga

Merck & Co Inc. DCF Valuation: Is The Stock Undervalued? ↗

July 19, 2024

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.

Via Talk Markets

Merck & Co's Options Frenzy: What You Need to Know ↗

July 18, 2024

Via Benzinga

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 30, 2024

Via Benzinga

Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer ↗

July 30, 2024

The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...

Via Benzinga

Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday? ↗

July 30, 2024

Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting.

Via Benzinga

MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024 ↗

July 30, 2024

MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

4 Stocks to Keep High on Your Buy List ↗

July 30, 2024

Be ready for opportunities.

Via The Motley Fool

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗

July 30, 2024

Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...

Via Benzinga

Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In ↗

July 30, 2024

Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on...

Via Benzinga

Topics Economy Stocks

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short ↗

July 30, 2024

Merck reported better-than-expected earnings on Tuesday. But the pharmaceutical giant's soft outlook could pressure Merck stock.

Via Investor's Business Daily

Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches ↗

July 25, 2024

The Dow index declined 1.3% on Wednesday, undercutting short-term support.

Via Investor's Business Daily

Topics Stocks

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants ↗

July 23, 2024

Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.

Via Benzinga

Billionaires Are Loading Up on This Surging Dow Stock. Should You? ↗

July 23, 2024

Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.

Via The Motley Fool

Topics Stocks

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗

July 21, 2024

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Via The Motley Fool

This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now. ↗

July 21, 2024

This fund has a basket of growth, income, and value stocks.

Via The Motley Fool

Topics ETFs

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits ↗

July 18, 2024

Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine.

Via Benzinga

Topics Lawsuit

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

Headline News about Merck & Co

Starting at $3.75/week.

Subscribe Today